424 related articles for article (PubMed ID: 22661587)
1. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.
Demetri GD; Garrett CR; Schöffski P; Shah MH; Verweij J; Leyvraz S; Hurwitz HI; Pousa AL; Le Cesne A; Goldstein D; Paz-Ares L; Blay JY; McArthur GA; Xu QC; Huang X; Harmon CS; Tassell V; Cohen DP; Casali PG
Clin Cancer Res; 2012 Jun; 18(11):3170-9. PubMed ID: 22661587
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
[TBL] [Abstract][Full Text] [Related]
3. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.
Reichardt P; Blay JY; Gelderblom H; Schlemmer M; Demetri GD; Bui-Nguyen B; McArthur GA; Yazji S; Hsu Y; Galetic I; Rutkowski P
Ann Oncol; 2012 Jul; 23(7):1680-7. PubMed ID: 22357255
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
Demetri GD; van Oosterom AT; Garrett CR; Blackstein ME; Shah MH; Verweij J; McArthur G; Judson IR; Heinrich MC; Morgan JA; Desai J; Fletcher CD; George S; Bello CL; Huang X; Baum CM; Casali PG
Lancet; 2006 Oct; 368(9544):1329-38. PubMed ID: 17046465
[TBL] [Abstract][Full Text] [Related]
5. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
Hsu CC; Wu CE; Chen JS; Tseng JH; Chiang KC; Liu YY; Tsai CY; Cheng CT; Chen TW; Jan YY; Yeh TS; Chen YY; Yeh CN
Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
[TBL] [Abstract][Full Text] [Related]
6. Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.
Adenis A; Blay JY; Bui-Nguyen B; Bouché O; Bertucci F; Isambert N; Bompas E; Chaigneau L; Domont J; Ray-Coquard I; Blésius A; Van Tine BA; Bulusu VR; Dubreuil P; Mansfield CD; Acin Y; Moussy A; Hermine O; Le Cesne A
Ann Oncol; 2014 Sep; 25(9):1762-1769. PubMed ID: 25122671
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate.
Shirao K; Nishida T; Doi T; Komatsu Y; Muro K; Li Y; Ueda E; Ohtsu A
Invest New Drugs; 2010 Dec; 28(6):866-75. PubMed ID: 19730791
[TBL] [Abstract][Full Text] [Related]
8. Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.
George S; Reichardt P; Lechner T; Li S; Cohen DP; Demetri GD
Ann Oncol; 2012 Dec; 23(12):3180-3187. PubMed ID: 22858558
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
George S; Blay JY; Casali PG; Le Cesne A; Stephenson P; Deprimo SE; Harmon CS; Law CN; Morgan JA; Ray-Coquard I; Tassell V; Cohen DP; Demetri GD
Eur J Cancer; 2009 Jul; 45(11):1959-68. PubMed ID: 19282169
[TBL] [Abstract][Full Text] [Related]
10. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.
Rutkowski P; Bylina E; Klimczak A; Switaj T; Falkowski S; Kroc J; Lugowska I; Brzeskwiniewicz M; Melerowicz W; Osuch C; Mierzejewska E; Wasielewski K; Woźniak A; Grzesiakowska U; Nowecki ZI; Siedlecki JA; Limon J
BMC Cancer; 2012 Mar; 12():107. PubMed ID: 22439647
[TBL] [Abstract][Full Text] [Related]
11. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.
Kang YK; Ryu MH; Yoo C; Ryoo BY; Kim HJ; Lee JJ; Nam BH; Ramaiya N; Jagannathan J; Demetri GD
Lancet Oncol; 2013 Nov; 14(12):1175-82. PubMed ID: 24140183
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy and safety of sunitinib on patients with imatinib-resistant gastrointestinal stromal tumor].
Liu X; Jiang WZ; Guan GX; Chen ZF; Chi P; Lu HS
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):221-5. PubMed ID: 23536339
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors.
Li J; Gao J; Hong J; Shen L
Future Oncol; 2012 May; 8(5):617-24. PubMed ID: 22646775
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.
Reichardt P; Kang YK; Rutkowski P; Schuette J; Rosen LS; Seddon B; Yalcin S; Gelderblom H; Williams CC; Fumagalli E; Biasco G; Hurwitz HI; Kaiser PE; Fly K; Matczak E; Chen L; Lechuga MJ; Demetri GD
Cancer; 2015 May; 121(9):1405-13. PubMed ID: 25641662
[TBL] [Abstract][Full Text] [Related]
15. Regorafenib: a guide to its use in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib and sunitinib.
Lyseng-Williamson KA
BioDrugs; 2013 Oct; 27(5):525-31. PubMed ID: 23975637
[TBL] [Abstract][Full Text] [Related]
16. Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure.
Deprimo SE; Huang X; Blackstein ME; Garrett CR; Harmon CS; Schöffski P; Shah MH; Verweij J; Baum CM; Demetri GD
Clin Cancer Res; 2009 Sep; 15(18):5869-77. PubMed ID: 19737953
[TBL] [Abstract][Full Text] [Related]
17. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure.
Demetri GD; Heinrich MC; Fletcher JA; Fletcher CD; Van den Abbeele AD; Corless CL; Antonescu CR; George S; Morgan JA; Chen MH; Bello CL; Huang X; Cohen DP; Baum CM; Maki RG
Clin Cancer Res; 2009 Sep; 15(18):5902-9. PubMed ID: 19737946
[TBL] [Abstract][Full Text] [Related]
18. Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability.
Kim KP; Ryu MH; Yoo C; Ryoo BY; Choi DR; Chang HM; Lee JL; Beck MY; Kim TW; Kang YK
Cancer Chemother Pharmacol; 2011 Aug; 68(2):285-91. PubMed ID: 20957481
[TBL] [Abstract][Full Text] [Related]
19. Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial.
Komatsu Y; Doi T; Sawaki A; Kanda T; Yamada Y; Kuss I; Demetri GD; Nishida T
Int J Clin Oncol; 2015 Oct; 20(5):905-12. PubMed ID: 25655899
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.
Montemurro M; Gelderblom H; Bitz U; Schütte J; Blay JY; Joensuu H; Trent J; Bauer S; Rutkowski P; Duffaud F; Pink D
Eur J Cancer; 2013 Mar; 49(5):1027-31. PubMed ID: 23140824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
